KBC Group
PHAT icon

KBC Group’s Phathom Pharmaceuticals PHAT Stock Holding History

KBC Group’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$563K Hold
77,139
– – ﹤0.01% 765
2026
Q2 		$837K Hold
77,139
– – ﹤0.01% 754
2026
Q1 		$857K Buy
+77,139
New +$974K ﹤0.01% 735

Other funds holding PHAT

Medicxi Ventures Management
Medicxi Ventures Management St. Helier, Jersey $127M AUM 21.77% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Catalys Pacific
Catalys Pacific Tokyo, Japan $210M AUM 33.18% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Kornitzer Capital Management
Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return
Penn Mutual Asset Management
Penn Mutual Asset Management Conshohocken, Pennsylvania $23.1M AUM 4.22% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

KBC Group's PHAT Position: Q3 2026 in Review

KBC Group held its Phathom Pharmaceuticals (PHAT) position steady in Q3 2026 at 77,139 shares worth $563K. The position accounts for ﹤0.01% of the portfolio, ranked #765.

KBC Group first reported a position in PHAT in Q1 2026 and has held it in 3 quarters since. The position peaked at $857K in Q1 2026. 33 funds tracked by Wall St. Rank hold PHAT as of Q3 2026.

  • KBC Group held 77,139 shares of Phathom Pharmaceuticals worth $563K as of Q3 2026.
  • KBC Group left its Phathom Pharmaceuticals share count unchanged in Q3 2026.
  • Phathom Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #765 holding.
  • KBC Group first reported a position in Phathom Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • KBC Group's Phathom Pharmaceuticals position peaked at $857K in Q1 2026.
  • 33 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.